345 related articles for article (PubMed ID: 32234404)
1. Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.
Chung MP; Richardson C; Kirakossian D; Orandi AB; Saketkoo LA; Rider LG; Schiffenbauer A; von Mühlen CA; Chung L; ;
Autoimmun Rev; 2020 Jun; 19(6):102533. PubMed ID: 32234404
[TBL] [Abstract][Full Text] [Related]
2. Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review.
Gonçalves Júnior J; Shinjo SK
Curr Rheumatol Rep; 2024 Feb; 26(2):53-68. PubMed ID: 38060107
[TBL] [Abstract][Full Text] [Related]
3. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
4. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis.
Duvvuri B; Pachman LM; Hermanson P; Wang T; Moore R; Ding-Hwa Wang D; Long A; Morgan GA; Doty S; Tian R; Sancak Y; Lood C
J Autoimmun; 2023 Jul; 138():103061. PubMed ID: 37244073
[TBL] [Abstract][Full Text] [Related]
5. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.
Bingham A; Mamyrova G; Rother KI; Oral E; Cochran E; Premkumar A; Kleiner D; James-Newton L; Targoff IN; Pandey JP; Carrick DM; Sebring N; O'Hanlon TP; Ruiz-Hidalgo M; Turner M; Gordon LB; Laborda J; Bauer SR; Blackshear PJ; Imundo L; Miller FW; Rider LG;
Medicine (Baltimore); 2008 Mar; 87(2):70-86. PubMed ID: 18344805
[TBL] [Abstract][Full Text] [Related]
6. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
7. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
Hoeltzel MF; Oberle EJ; Robinson AB; Agarwal A; Rider LG
Curr Rheumatol Rep; 2014 Dec; 16(12):467. PubMed ID: 25366934
[TBL] [Abstract][Full Text] [Related]
8. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues.
Davuluri S; Duvvuri B; Lood C; Faghihi-Kashani S; Chung L
Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101768. PubMed ID: 35803868
[TBL] [Abstract][Full Text] [Related]
9. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.
Wienke J; Deakin CT; Wedderburn LR; van Wijk F; van Royen-Kerkhof A
Front Immunol; 2018; 9():2951. PubMed ID: 30619311
[TBL] [Abstract][Full Text] [Related]
10. Update on the treatment of calcinosis in dermatomyositis.
Shinjo SK; Souza FH
Rev Bras Reumatol; 2013 Apr; 53(2):211-4. PubMed ID: 23856799
[TBL] [Abstract][Full Text] [Related]
11. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?
Valenzuela A; Chung L
J Scleroderma Relat Disord; 2022 Feb; 7(1):7-23. PubMed ID: 35386947
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
Gunawardena H; Wedderburn LR; Chinoy H; Betteridge ZE; North J; Ollier WE; Cooper RG; Oddis CV; Ramanan AV; Davidson JE; McHugh NJ;
Arthritis Rheum; 2009 Jun; 60(6):1807-14. PubMed ID: 19479859
[TBL] [Abstract][Full Text] [Related]
14. Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment.
Pinotti CS; Cannon L; Dvergsten JA; Wu EY
Front Med (Lausanne); 2023; 10():1155839. PubMed ID: 36936211
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of juvenile-onset clinically amyopathic dermatomyositis.
Gerami P; Walling HW; Lewis J; Doughty L; Sontheimer RD
Br J Dermatol; 2007 Oct; 157(4):637-44. PubMed ID: 17596148
[TBL] [Abstract][Full Text] [Related]
16. Linear morphea with overlying lichen sclerosus and calcinosis cutis associated with juvenile dermatomyositis.
Kaur M; Sadhukhan S; Bhardwaj A; Patra S; Rao M; Alam A
Pediatr Dermatol; 2023; 40(3):500-502. PubMed ID: 36384242
[TBL] [Abstract][Full Text] [Related]
17. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Paik JJ; Lubin G; Gromatzky A; Mudd PN; Ponda MP; Christopher-Stine L
Clin Exp Rheumatol; 2023 Mar; 41(2):348-358. PubMed ID: 35766013
[TBL] [Abstract][Full Text] [Related]
18. Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center.
Nitiyarom R; Charuvanij S; Likasitwattanakul S; Thanoophunchai C; Wisuthsarewong W
Indian J Dermatol Venereol Leprol; 2022; 88(2):162-170. PubMed ID: 34491668
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
[TBL] [Abstract][Full Text] [Related]
20. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
